Aquinnah Pharmaceuticals Obtains $5,000,000 New Financing

  • Feed Type
  • Date
    12/22/2015
  • Company Name
    Aquinnah Pharmaceuticals
  • Mailing Address
    700 Main Street North Cambridge, MA 02139 USA
  • Company Description
    Aquinnah Pharmaceutical’s approach is unique by integrating human genetic, human pathology and cellular biology R&D expertise, towards the development of a new therapeutic approach. Our approach has the potential to treat the majority of patients with ALS (Amyotrophic Lateral Sclerosis), also known as Lou Gehrig’s disease.
  • Website
    http://www.aquinnahpharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $5,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    This funding adds further momentum to the numerous peer reviewed grants that we have received and will accelerate our program toward clinical development of new drugs for ALS and other neurodegenerative diseases.
  • M&A Terms
  • Venture Investor
    Takeda Ventures

Trending on Xconomy